Methotrexate in Rheumatoid Arthritis – 2015: New Facts and Ideas

Nasonov, E.

doi:10.14412/1995-4484-2015-64-76

Cited by 5 publications

(1 citation statement)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Метотрексат-антиметаболит фолиевой кислоты (витамин В9), который обладает цитостатическими и иммуносупрессивными свой ствами [4]. Данный препарат получил широкое применение для лечения ЮИА и в полной мере отвечает основным принципам программы «Treat to target» («Лечение до достижения цели»), разработанной экспертами 25 стран Европы, Америки, Австралии, Японии [5].…”

Section: Introductionunclassified

Gut microbiota and methotrexate in children with juvenile idiopathic arthritis

Zhukov,

Malievsky,

Nizhevich

2024

jour

View full text Add to dashboard Cite

Introduction. Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children [1]. The etiology of the disease is currently unknown, but there are many works on the role of the intestinal microbiota in JIA and its interaction with antirheumatic drugs (methotrexate). There are a number of data on the effect of methotrexate on the intestinal microbiota. The article provides a review of the literature on the involvement of the intestinal microbiota in the induction of autoinflammation and the possible antagonism between the intestinal microbiota and methotrexate.

show abstract

Section: Introductionunclassified

Gut microbiota and methotrexate in children with juvenile idiopathic arthritis

Zhukov,

Malievsky,

Nizhevich

2024

jour

View full text Add to dashboard Cite

show abstract

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations

Nasonov¹

2016

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The paper considers a current strategy, international and Russian recommendations for the pharmacotherapy of rheumatoid arthritis (RA), one of the most common and severe human immune-mediated inflammatory diseases. It emphasizes the need for early diagnosis and therapy with disease-modifying antirheumatic drugs, primarily methotrexate (MT), starting at the onset of the disease, and careful monitoring of therapeutic effectiveness, allowing RA remission to be achieved with a treatment-to-target strategy. The author discusses recent RA pharmacotherapy advances that are related to the rational use of MT, biological agents, and the new targeted JAK inhibitor tofacitinib.

show abstract

Cardiovascular disease in rheumatic diseases

2016

View full text Add to dashboard Cite

The representatives of immunoinflammatory diseases are rheumatic ones, such as primarily rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, and other systemic connective diseases, which are characterized by a high risk for untimely death. The high risk of untimely death in these diseases has been found to be associated with the severity of an immunoinflammatory process that gives rise to severe irreversible damage to vital organs and systems and with the development of a wide spectrum of comorbidities (infections, interstitial lung disease, malignant tumors, osteoporotic fractures, etc.). Among them, diseases of the cardiovascular system, which are most commonly caused by the early development and.accelerated progression of atherosclerotic coronary lesions, hold a central.position. The paper gives the data available in the recent literature on the impact.of antirheumatic therapy (disease-modifying antirheumatic drugs and biological agents) on' the cardiovascular system.

show abstract

Methotrexate in Rheumatoid Arthritis – 2015: New Facts and Ideas

Cited by 5 publications

References 106 publications

Gut microbiota and methotrexate in children with juvenile idiopathic arthritis

Gut microbiota and methotrexate in children with juvenile idiopathic arthritis

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations

Cardiovascular disease in rheumatic diseases

Contact Info

Product

Resources

About